Tempus studied over 5,500 advanced NSCLC patients and found that using both RNA and DNA sequencing identified significantly more actionable genetic variants than DNA testing alone—boosting detection ...
At ASH's annual meeting, a study showed the potential for this method to inform the next treatment after patients relapse on BCMA- or GPRC5D-targeted therapy.